RusNano still has $6B to invest in nanobio; Biotie in talks with alternative partners for Alzheimer's drug;

@FierceBiotech: Google software could aid drug design. Article | Follow @FierceBiotech

@JohnCFierce: Dealmaking rule no. 1: always claim to have multiple bidders interested in a product. Like Biotie on Alzheimer's program. More | Follow @JohnCFierce

@RyanMFierce: Here's my take and some inside dope one of biopharma's hottest job markets. Piece | Follow @RyanMFierce

@MarkHFierce: I'll start with something slightly off topic because it is so unbelievably cool. Scientists sprout an ancient plant. Story | Follow @MarkHFierce

> Institutional Investor takes a look at RusNano, which has another $6 billion to invest in nanotech and nanobio companies. Story

> Finland's Biotie claims it is unconcerned whether Roche ($RHHBY) will exercise an option on its Alzheimer's program. The CEO says it has other interested partners waiting in the wings in case Roche passes on the treatment. Report

> Israel's So-Gel Technologies says it has inked a $27 million deal with a U.S. pharma company for a new dermatological drug. Report

> Lumena Pharmaceuticals has raised $2 million for its work on diabetes treatments. Story

Pharma News

@FiercePharma: New M&A regs won't put a damper on Indian pharma deals, survey finds. More | Follow @FiercePharma

> Quebec plant fixes force Sandoz to slash output. Story

> FDA brings Sun's Doxil copy online to fix shortage. Piece

> With Hisun JV inked, Pfizer eyes other Chinese tie-ups. Article

> Pfizer reportedly weighing animal health IPO. More

IT News

> Oracle aids Moffitt Cancer Center’s IT system for speeding patient recruitment. Article

> Global Alzheimer's researchers seek cloud-based infrastructure to share data. News

> Eisai's H3 Biomedicine taps cancer genomics software for drug discovery effort. More

> Big Pharma activity eyed in mobile trends. Item

Manufacturing News

> Hospira on track with expansions in India. Story

> Leader of Pakistan drugmakers resigns in frustration. News

> Avastin alert likely to revive discussion of pharma-financed tracking system. Article

> Teva halts production of drug in U.K. Item

Research News

> Engineered measles virus prolongs lifespan of brain cancer-stricken mice. More

> Amniotic stem cells boost kidney disease survival time. Story

> Tobacco-chewing may damage crucial gene. Item

> Humans to test T-cell treatment that subdued canine lymphoma. Article

> Flu, over time, could increase Alzheimer's vulnerability. Piece

> Can omega-3 fatty acids beat back cancer? Maybe not. More

And Finally... Investigators say hepatitis has now become more deadly than HIV in the U.S. Report

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.